List view / Grid view
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
Aortic atherosclerotic plaque inflammation may contribute to the progression of non-alcoholic fatty liver disease to liver fibrosis...
A new study by the University of Arizona (UA) suggests that revealing all the steps required to activate an enzyme called a protein kinase may help identify new ways to target cancer.
Euro Metabolomics 2018 will be a platform to investigate on recent research and advancements that can be useful to the researchers.
Scientists have investigated a key protein used in drug design and discovered dynamic structural features that may lead to new ways to target diseases...
The study of biochemistry provides molecular insights into how the human population ages, how diseases commence and progress, how molecular changes relate to disease remission and relapse, and how humans respond to treatments...
29 February 2016 | By Victoria White
ProTx-II, a peptide toxin found within the venom of the Peruvian green velvet tarantula, has a high potency and selectivity to inhibit the pain sensation receptor...
17 July 2015 | By Victoria White
Scientists have found that existing anti-malaria drugs, Chloroquine and Amodiaquine, could be a potential treatment for Parkinson's disease...
Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…
